By Peter Loftus
Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu.
Moderna and Novavax shares rose more than 10%, while CureVac increased 5%.
The companies are developing experimental vaccines against pandemic influenza, including the avian H5N1 strain that has infected more than 60 people in the U.S. in the past year, mostly from animal-to-human exposures.
Moderna's efforts are part of a $176 million federal contract it received last year.
The death in Louisiana could spur more federal funding for the vaccines' development, or purchase orders if the vaccines succeed in testing and are authorized by regulators. A vaccine could be given to at-risk people such as farm workers, hunters or bird hobbyists.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 07, 2025 13:40 ET (18:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。